Compile Data Set for Download or QSAR
Report error Found 16 Enz. Inhib. hit(s) with all data for entry = 10435
TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Human)
Neuropore Therapies

US Patent
LigandPNGBDBM535713(4-methyl-5-(6-morpholino-4- (phenylsulfonyl)pyridi...)
Affinity DataIC50: 19nMAssay Description:The substrate (Phosphatidylinositol (PI): Phosphatidylserine (PS)) was added to freshly prepared reaction buffer (40 mM Tris-HCl (pH7.5), 3 μM O...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Human)
Neuropore Therapies

US Patent
LigandPNGBDBM535651(5-(6-morpholino-4- (phenylsulfonyl)pyridin-2- yl)t...)
Affinity DataIC50: 81nMAssay Description:The substrate (Phosphatidylinositol (PI): Phosphatidylserine (PS)) was added to freshly prepared reaction buffer (40 mM Tris-HCl (pH7.5), 3 μM O...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Human)
Neuropore Therapies

US Patent
LigandPNGBDBM535714(5-(6-morpholino-4- phenoxypyridin-2-yl)thiazol-2- ...)
Affinity DataIC50: 150nMAssay Description:The substrate (Phosphatidylinositol (PI): Phosphatidylserine (PS)) was added to freshly prepared reaction buffer (40 mM Tris-HCl (pH7.5), 3 μM O...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Human)
Neuropore Therapies

US Patent
LigandPNGBDBM535712(5-(6-morpholino-4- (phenylsulfonyl)pyridin-2-yl)-4...)
Affinity DataIC50: 287nMAssay Description:The substrate (Phosphatidylinositol (PI): Phosphatidylserine (PS)) was added to freshly prepared reaction buffer (40 mM Tris-HCl (pH7.5), 3 μM O...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

LigandPNGBDBM535651(5-(6-morpholino-4- (phenylsulfonyl)pyridin-2- yl)t...)
Affinity DataIC50: 502nMAssay Description:Compounds were prepared at 100× final concentration using a 12-point, 1:3 serial-dilution in DMSO, with DMSO control as the 12th point. Compound was ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

LigandPNGBDBM535569((R)-5-(3-morpholino-5- ((tetrahydrofuran-3- yl)sul...)
Affinity DataIC50: 740nMAssay Description:Compounds were prepared at 100× final concentration using a 12-point, 1:3 serial-dilution in DMSO, with DMSO control as the 12th point. Compound was ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

LigandPNGBDBM535559((R)-5-(3-morpholino-5- ((tetrahydrofuran-3- yl)sul...)
Affinity DataIC50: 750nMAssay Description:Compounds were prepared at 100× final concentration using a 12-point, 1:3 serial-dilution in DMSO, with DMSO control as the 12th point. Compound was ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Human)
Neuropore Therapies

US Patent
LigandPNGBDBM535594(5-(3-morpholino-5- (phenylsulfonyl)phenyl)-1,3,4- ...)
Affinity DataIC50: 1.60E+3nMAssay Description:The substrate (Phosphatidylinositol (PI): Phosphatidylserine (PS)) was added to freshly prepared reaction buffer (40 mM Tris-HCl (pH7.5), 3 μM O...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Human)
Neuropore Therapies

US Patent
LigandPNGBDBM535569((R)-5-(3-morpholino-5- ((tetrahydrofuran-3- yl)sul...)
Affinity DataIC50: 2.10E+3nMAssay Description:The substrate (Phosphatidylinositol (PI): Phosphatidylserine (PS)) was added to freshly prepared reaction buffer (40 mM Tris-HCl (pH7.5), 3 μM O...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Human)
Neuropore Therapies

US Patent
LigandPNGBDBM535614(5-(3-morpholino-5- (phenylsulfonyl)phenyl)-1,2,4- ...)
Affinity DataIC50: 2.20E+3nMAssay Description:The substrate (Phosphatidylinositol (PI): Phosphatidylserine (PS)) was added to freshly prepared reaction buffer (40 mM Tris-HCl (pH7.5), 3 μM O...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

LigandPNGBDBM535594(5-(3-morpholino-5- (phenylsulfonyl)phenyl)-1,3,4- ...)
Affinity DataIC50: 2.20E+3nMAssay Description:Compounds were prepared at 100× final concentration using a 12-point, 1:3 serial-dilution in DMSO, with DMSO control as the 12th point. Compound was ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

LigandPNGBDBM535713(4-methyl-5-(6-morpholino-4- (phenylsulfonyl)pyridi...)
Affinity DataIC50: 2.30E+3nMAssay Description:Compounds were prepared at 100× final concentration using a 12-point, 1:3 serial-dilution in DMSO, with DMSO control as the 12th point. Compound was ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

LigandPNGBDBM535714(5-(6-morpholino-4- phenoxypyridin-2-yl)thiazol-2- ...)
Affinity DataIC50: 3.42E+3nMAssay Description:Compounds were prepared at 100× final concentration using a 12-point, 1:3 serial-dilution in DMSO, with DMSO control as the 12th point. Compound was ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

TargetPhosphatidylinositol 3-kinase catalytic subunit type 3(Human)
Neuropore Therapies

US Patent
LigandPNGBDBM535559((R)-5-(3-morpholino-5- ((tetrahydrofuran-3- yl)sul...)
Affinity DataIC50: 3.80E+3nMAssay Description:The substrate (Phosphatidylinositol (PI): Phosphatidylserine (PS)) was added to freshly prepared reaction buffer (40 mM Tris-HCl (pH7.5), 3 μM O...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

LigandPNGBDBM535712(5-(6-morpholino-4- (phenylsulfonyl)pyridin-2-yl)-4...)
Affinity DataIC50: 5.24E+3nMAssay Description:Compounds were prepared at 100× final concentration using a 12-point, 1:3 serial-dilution in DMSO, with DMSO control as the 12th point. Compound was ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent

LigandPNGBDBM535614(5-(3-morpholino-5- (phenylsulfonyl)phenyl)-1,2,4- ...)
Affinity DataIC50: 1.12E+4nMAssay Description:Compounds were prepared at 100× final concentration using a 12-point, 1:3 serial-dilution in DMSO, with DMSO control as the 12th point. Compound was ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/6/2022
Entry Details
Go to US Patent